Darren J Moore

List of Publications by Citations

73 papers	12,962 citations	42 h-index	74 g-index
74 ext. papers	14,467 ext. citations	6.5 avg, IF	5.74 L-index

#	Paper	IF	Citations
73	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
72	PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 378-83	11.5	1199
71	Molecular pathophysiology of Parkinson's disease. *Annual Review of Neuroscience*, **2005**, 28, 57-87	17	982
70	Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 16842-7	11.5	933
69	Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. *Human Molecular Genetics*, **2007**, 16, 223-32	5.6	466
68	Localization of LRRK2 to membranous and vesicular structures in mammalian brain. *Annals of Neurology*, **2006**, 60, 557-69	9.4	429
67	Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. *Journal of Biological Chemistry*, **2012**, 287, 15345-64	5.4	375
66	Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 18676-81	11.5	359
65	Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. *Human Molecular Genetics*, **2005**, 14, 2063-73	5.6	348
64	Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. *PLoS ONE*, **2011**, 6, e18568	3.7	297
63	Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. *Human Molecular Genetics*, **2005**, 14, 71-84	5.6	218
62	Parkin promotes the ubiquitination and degradation of the mitochondrial fusion factor mitofusin 1. *Journal of Neurochemistry*, **2011**, 118, 636-45	6	185
61	A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. *Journal of Neurochemistry*, **2003**, 87, 1558-67	6	173
60	GTPase activity plays a key role in the pathobiology of LRRK2. *PLoS Genetics*, **2010**, 6, e1000902	6	163
59	CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 2897-902	11.5	160
58	The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. *Journal of Neuroscience*, **2008**, 28, 3384-91	6.6	158
57	A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. *Journal of Neuroscience*, **2011**, 31, 907-12	6.6	125

56	Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. *Brain Research*, **2007**, 1155, 208-19	3.7	125
55	PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity. *Human Molecular Genetics*, **2012**, 21, 1725-43	5.6	124
54	LRRK2 secretion in exosomes is regulated by 14-3-3. *Human Molecular Genetics*, **2013**, 22, 4988-5000	5.6	122
53	Dynamic and redundant regulation of LRRK2 and LRRK1 expression. *BMC Neuroscience*, **2007**, 8, 102	3.2	121
52	GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. *PLoS Genetics*, **2012**, 8, e1002526	6	108
51	Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration. *Human Molecular Genetics*, **2014**, 23, 4621-38	5.6	104
50	GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2. *Human Molecular Genetics*, **2013**, 22, 1140-56	5.6	93
49	Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. *Human Molecular Genetics*, **2014**, 23, 2055-77	5.6	93
48	Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. *Journal of Neurochemistry*, **2007**, 100, 368-81	6	88
47	VPS35, the Retromer Complex and Parkinson's Disease. *Journal of Parkinson's Disease*, **2017**, 7, 219-233	5.3	84
46	Parkin mediates the degradation-independent ubiquitination of Hsp70. *Journal of Neurochemistry*, **2008**, 105, 1806-19	6	81
45	Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration. *Acta Neuropathologica Communications*, **2019**, 7, 41	7.3	77
44	Neurodegenerative phenotypes in an A53T □synuclein transgenic mouse model are independent of LRRK2. *Human Molecular Genetics*, **2012**, 21, 2420-31	5.6	69
43	Mitochondrial dysfunction in genetic animal models of Parkinson's disease. *Antioxidants and Redox Signaling*, **2012**, 16, 896-919	8.4	67
42	Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. *Molecular Neurodegeneration*, **2009**, 4, 34	19	65
41	Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. *Journal of Neuropathology and Experimental Neurology*, **2009**, 68, 994-1005	3.1	65
40	Mechanisms of LRRK2-mediated neurodegeneration. *Current Neurology and Neuroscience Reports*, **2012**, 12, 251-60	6.6	55
39	Parkinson's disease-linked knockin mice manifest tau neuropathology and dopaminergic neurodegeneration. *Proceedings of the National Academy of Sciences of the United States of America* , **2019**, 116, 5765-5774	11.5	50

38	Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. *Neurobiology of Disease*, **2014**, 71, 345-58	7.5	49
37	Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease. *Human Molecular Genetics*, **2016**, 25, 5365-5382	5.6	47
36	Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses. *NeuroMolecular Medicine*, **2003**, 4, 95-108	4.6	47
35	Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonism. *PLoS ONE*, **2012**, 7, e39942	3.7	44
34	Contribution of GTPase activity to LRRK2-associated Parkinson disease. *Small GTPases*, **2013**, 4, 164-70	2.7	42
33	Localization of MAP1-LC3 in vulnerable neurons and Lewy bodies in brains of patients with dementia with Lewy bodies. *Journal of Neuropathology and Experimental Neurology*, **2011**, 70, 264-80	3.1	42
32	Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2. *Journal of Biological Chemistry*, **2010**, 285, 29569-76	5.4	42
31	Parkin functionally interacts with PGC-1 to preserve mitochondria and protect dopaminergic neurons. *Human Molecular Genetics*, **2017**, 26, 582-598	5.6	41
30	A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity. *Human Molecular Genetics*, **2014**, 23, 4887-905	5.6	41
29	Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease. *Neurobiology of Disease*, **2015**, 77, 49-61	7.5	39
28	Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1. *Nature Communications*, **2016**, 7, 11792	17.4	38
27	Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting. *Human Molecular Genetics*, **2018**, 27, 3189-3205	5.6	37
26	Value of genetic models in understanding the cause and mechanisms of Parkinson's disease. *Current Neurology and Neuroscience Reports*, **2008**, 8, 288-96	6.6	37
25	Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation. *Biochemical Society Transactions*, **2017**, 45, 163-172	5.1	36
24	Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations. *PLoS ONE*, **2012**, 7, e47784	3.7	36
23	Divergent -synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. *Neurobiology of Disease*, **2013**, 58, 183-90	7.5	34
22	Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal -synuclein preformed fibrils. *Neurobiology of Disease*, **2019**, 130, 104525	7.5	33
21	Genetic mouse models of neurodegenerative diseases. *Progress in Molecular Biology and Translational Science*, **2011**, 100, 419-82	4	33

20	Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity. *Advances in Neurobiology*, **2017**, 14, 71-88	2.1	32
19	Detrimental deletions: mitochondria, aging and Parkinson's disease. *BioEssays*, **2006**, 28, 963-7	4.1	28
18	Lessons from Drosophila models of DJ-1 deficiency. *Science of Aging Knowledge Environment: SAGE KE*, **2006**, 2006, pe2		26
17	Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9). *Neurobiology of Disease*, **2015**, 73, 229-43	7.5	24
16	The biology and pathobiology of LRRK2: implications for Parkinson's disease. *Parkinsonism and Related Disorders*, **2008**, 14 Suppl 2, S92-8	3.6	22
15	G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain. *Human Molecular Genetics*, **2018**, 27, 120-134	5.6	21
14	Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 17296-17307	11.5	20
13	Modeling LRRK2 Pathobiology in Parkinson's Disease: From Yeast to Rodents. *Current Topics in Behavioral Neurosciences*, **2015**, 22, 331-68	3.4	16
12	LRRK2 and the Endolysosomal System in Parkinson's Disease. *Journal of Parkinson's Disease*, **2020**, 10, 1271-1291	5.3	15
11	Parkin reinvents itself to regulate fatty acid metabolism by tagging CD36. *Journal of Clinical Investigation*, **2011**, 121, 3389-92	15.9	14
10	Endosomal sorting pathways in the pathogenesis of Parkinson's disease. *Progress in Brain Research*, **2020**, 252, 271-306	2.9	8
9	LRRK2 and Protein Aggregation in Parkinson's Disease: Insights From Animal Models. *Frontiers in Neuroscience*, **2020**, 14, 719	5.1	6
8	Revelations and revolutions in the understanding of Parkinson's disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2009**, 1792, 585-6	6.9	3
7	Deciphering the role of VPS35 in Parkinson's disease. *Journal of Neuroscience Research*, **2018**, 96, 1339-1340	4.4	3
6	Multiple genetic pathways regulating lifespan extension are neuroprotective in a G2019S LRRK2 nematode model of Parkinson's disease. *Neurobiology of Disease*, **2021**, 151, 105267	7.5	2
5	Neuronal deletion induces spinal cord motor neuron degeneration and early post-natal lethality. *Brain Communications*, **2021**, 3, fcab208	4.5	2
4	Mechanisms of -Mediated Neurodegeneration in Parkinson's Disease.. *International Review of Movement Disorders*, **2021**, 2, 221-244		1
3	Dopaminergic Neurodegeneration Induced by Parkinson's Disease-Linked G2019S LRRK2 is Dependent on Kinase and GTPase Activity		1

2	Understanding the contributions of VPS35 and the retromer in neurodegenerative disease.. *Neurobiology of Disease*, **2022**, 105768	7.5	1
1	Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity. *Journal of Parkinson's Disease*, **2022**, 1-25	5.3	0